A recent study demonstrated that long-term, low-dose trimethoprim-sulfamethoxazole (TMP-SMX) was associated with a modest decrease in urinary tract infections (UTIs) in children who had had at least 1 such symptomatic infection in the past.
A recent study demonstrated that long-term, low-dose trimethoprim-sulfamethoxazole (TMP-SMX) was associated with a modest decrease in urinary tract infections (UTIs) in children who had had at least 1 such symptomatic infection in the past. The study was conducted in 576 youngsters from birth to 18 years of age recruited from 9 centers in Australia; median age was 14 months.
After a 2-week run-in period during which all children received TMP-SMX, half the participants continued the drug and half were given placebo. The children were seen at 3-month intervals, when the study drug was dispensed, during the 12-month follow-up. The single daily dose was calculated by volume according to body weight (2 mg of TMP plus 10 mg of SMX per kilogram).
During the study period, UTI was diagnosed in 13% of patients in the antibiotic group and in 19% in the placebo group. At 12 months, 14 patients therefore would need to have been treated to prevent 1 UTI. Escherichia coli was the chief causative bacterium in both groups-responsible for 83% of infections among antibiotic recipients and 84% of infections among placebo recipients. The findings were not significantly affected by variables such as age, sex, urinary reflux status, and number of previous UTIs (Craig JC, et al. N Engl J Med. 2009;361[18]:1748-1759).
This study offers faint praise for antibiotic prophylaxis in UTIs. Fourteen person-years of antibiotics seem like a high price to pay to prevent 1 UTI, especially when the price includes medication cost, medication side effects, and antibiotic resistance. This study included children with all grades of urinary reflux and those with recurrent infection. Perhaps ongoing studies will define a more limited population for which the benefit of prophylaxis warrants all the costs.-MB
CDC recommends nirsevimab be prioritized for highest-risk infants amid limited availability
October 26th 2023The Centers for Disease Control and Prevention is advising providers to prioritize 100 mg doses of nirsevimab, a monoclonal antibody FDA-approved to prevent respiratory syncytial virus (RSV), for infants at the highest risk of severe RSV disease.
Navigating a complex case of pediatric COVID-19 with immunomodulatory therapies
October 21st 2023Eculizumab and anakinra should be considered in critically ill patients with severe infections that require immunomodulating therapies for life-threatening dysregulation, according to a poster session at the 2023 American Academy of Pediatrics National Conference & Exhibition.